Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Caribou Biosciences (CRBU) Asset Writedowns and Impairment (2025)

Caribou Biosciences has reported Asset Writedowns and Impairment over the past 1 years, most recently at $2.2 million for Q2 2025.

Quarterly Asset Writedowns and Impairment changed N/A to $2.2 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $2.2 million through Dec 2025, changed N/A year-over-year, with the annual reading at $12.1 million for FY2025, N/A changed from the prior year.
Asset Writedowns and Impairment was $2.2 million for Q2 2025 at Caribou Biosciences, down from $9.2 million in the prior quarter.
Over five years, Asset Writedowns and Impairment peaked at $9.2 million in Q1 2025 and troughed at $2.2 million in Q2 2025.